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Available online 4 June 2013Abstract Our work aimed at evaluating the role of adipose stem cells (ASC) on chondrocytes from osteoarthritic (OA) patients
and identifying the mediators involved. We used primary chondrocytes, ASCs from different sources and bone marrow
mesenchymal stromal cells (MSC) from OA donors. ASCs or MSCs were co-cultured with chondrocytes in a minimal medium and
using cell culture inserts. Under these conditions, ASCs did not affect the proliferation of chondrocytes but significantly
decreased camptothecin-induced apoptosis. Both MSCs and ASCs from different sources allowed chondrocytes in the cocultures
maintaining a stable expression of markers specific for a mature phenotype, while expression of hypertrophic and fibrotic
markers was decreased. A number of factors known to regulate the chondrocyte phenotype (IL-1β, IL-1RA, TNF-α) and matrix
remodeling (TIMP-1 and -2, MMP-1 and -9, TSP-1) were not affected. However, a significant decrease of TGF-β1 secretion by
chondrocytes and induction of HGF secretion by ASCs was observed. Addition of a neutralizing anti-HGF antibody reversed the
anti-fibrotic effect of ASCs whereas hypertrophic markers were not modulated. In summary, ASCs are an interesting source of
stem cells for efficiently reducing hypertrophy and dedifferentiation of chondrocytes, at least partly via the secretion of HGF.
This supports the interest of using these cells in therapies for osteo-articular diseases.
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Osteoarthritis (OA) is the most frequent rheumatic disease,
characterized by a degeneration of articular cartilage, mainly
due to changes in the activity of chondrocytes in favor of
835Adipose mesenchymal stem cells protect chondrocytes from degenerationcatabolic activity as well as reduced cartilage cellularity
(Bijlsma et al., 2011; Loeser et al., 2012). The capacity of
adult articular chondrocytes to regenerate the normal
cartilage matrix architecture declines with aging, due to cell
death (apoptosis) and abnormal responsiveness to anabolic
stimuli. OA chondrocytes lose their capacity to secrete the
specific components of the extracellular matrix, such as
collagen type IIB or aggregan, and adopt a hypertrophic or
fibroblastic phenotype. Currently, no treatment capable of
markedly altering the progression of OA exists and therapeutic
options are essentially pain management and surgical inter-
vention (Hunter, 2011). Indeed, new innovative therapeutic
strategies for cartilage protection/repair are currently being
evaluated mainly based on stem cell-mediated approaches.
Mesenchymal stem cells or stromal cells which reside in
bone marrow (MSCs) or in adipose tissue (adipose-derived
stromal cells or ASC) are capable of self-renew and are
characterized by their differentiation capabilities toward
three lineages namely, chondrocytes, osteoblasts and adipo-
cytes (Dominici et al., 2006). Beside this property, MSCs
produce a number of secreted factors, such as cytokines,
chemokines or growth factors, which mediate diverse func-
tions (Doorn et al., 2012; Meirelles Lda et al., 2009; Salgado et
al., 2010). Indeed, the use of MSCs for stem cell-based therapy
of degenerative diseases such as OA may rely on two modes of
action: MSC differentiation into chondrocytes, or prevention
of cartilage degeneration through secretion of bioactive
factors. Previous studies have demonstrated the potent role
of MSCs combined with biomaterials and chondrogenesis-
inducing factors for cartilage engineering (Vinatier et al.,
2009). Moreover, the co-culture of human MSCs with OA
chondrocytes allowed the differentiation of MSCs towards
chondrocytes in the absence of growth factors and prevented
their hypertrophic differentiation frequently occurring during
in vitro growth factor-induced chondrogenesis (Aung et al.,
2011). The possibility that MSCs, through their trophic role,
may prevent cartilage degradation or stimulate cartilage
formation would be of interest for the treatment of OA.
Recent works have shown that trophic factors secreted by
MSCs regulate the chondrocyte phenotype when the two cells
were mixed in pellet- or alginate-based co-cultures (Mo et al.,
2009; Wu et al., 2011, 2012). Altogether, these studies have
highlighted the role of the cross-talk between MSCs and
chondrocytes with an improved chondrogenic differentiation
of MSCs by factors secreted by chondrocytes and the positive
role of MSC trophic mediators on chondrocyte phenotype.
Most of these studies were conducted using bone marrow-
derived MSCs and less data are available on ASCs. These last
cells have been intensively tested in various pre-clinical
models since their initial characterization and are considered
as amore accessible source of cells than MSCs with comparable
properties (Pittenger et al., 1999; Zuk et al., 2001). However,
neither the effect of ASC or MSC secretome when these cells
are cultured with chondrocytes in the absence of direct
contact, nor the identification of the proteins responsible for
the paracrine effects, has been investigated.
In the present study, we therefore evaluated in vitro the
effects of factors secreted by ASCs on the proliferation,
apoptosis and phenotype of OA chondrocytes in a co-culture
assay where chondrocytes were physically separated from
ASCs by a porous membrane and cultured in a minimal
medium. Our main findings show that ASCs reduce theexpression of both hypertrophic and fibroblastic markers on
OA chondrocytes and that HGF is one key mediator involved
in the anti-fibrotic effect of ASCs.
Materials and methods
Tissue samples
Samples for ASC isolation were obtained from patients
undergoing plastic surgery or total joint replacement surgery
(hip or knee hoffa). Subcutaneous abdominal fat (SC-ASC) was
obtained from 17 patients (15 women and 2 men; mean age:
44.9 ± 4.3 years). Infrapatellar Hoffa (Hoffa-ASC) and hip fat
(Hip-ASC) were also obtained from OA patients. Chondrocytes
and MSCs were isolated from patients with OA undergoing
total knee replacement surgery. Articular cartilage was
harvested from the femoral condyles of 12 patients (10
women and 2 men; mean age: 68.9 ± 2.3 years; body max
index (BMI): 26.6 ± 1.4). MSCs were from 4 patients (3 women
and 1 man; mean age: 68 ± 3.7 years). Consent of donors was
approved by the French Ministry of Research and Innovation
(approvals DC2009-1052 and DC-2010-1185).
Cell isolation
For ASC isolation, adipose tissue was digested with 250 U/mL
collagenase type II for 1 h at 37 °C and centrifuged (300 g for
10 min) using routine laboratory practices. The stroma
vascular fraction was collected and cells filtered successively
through a 100 μm, 70 μm and 40 μm porous membrane (Cell
Strainer, BD-Biosciences, Le-Pont-de-Claix, France). Single
cells were seeded at the initial density of 4000 cell/cm2 in
αMEM supplemented with 100 U/mL penicillin/streptomycin
(PS), and 2 mmol/mL glutamine (Glu) and 10% fetal calf serum
(FCS) was from PAA laboratories (Mureaux, France). After
24 h, cultures were washed twice with PBS. After 1 week,
cells were trypsinized and expanded at 2000 cells/cm2 till day
14 (end of passage 1), where ASC preparations were used.
Clinical grade ASCs were isolated and expanded in
platelet-enriched plasma (PLP) as described (Bourin et al.,
2011). Typically, the doubling time of ASCs was evaluated to
be 1.25 ± 0.05 days.
For MSC isolation, trabecular bone pieces were flushed out
and cultured as previously described (Bouffi et al., 2010b). For
chondrocyte isolation, knee cartilage slices were incubated in
2.5 mg/mL pronase (Sigma-Aldrich, Saint-Quentin-Fallavier,
France) for 1 h at 37 °C followed by 2 mg/mL collagenase
type II (Sigma), overnight at 37 °C. Digested pieces were
filtrated through a 70 μm cell strainer and the cell suspension
was cultured in DMEM/PS/Glu/10% FCS (proliferativemedium)
at the density of 25,000 cell/cm2 till the end of passage 1.
Flow cytometry analysis
ASCs (1 × 105) in PBS containing 0.2% bovine serum albumin
(BSA) were incubated with different antibodies (BD-Biosci-
ences): fluorescein isothiocyanate (FITC)-conjugated CD31 or
CD106 antibodies, peridinin chlorophyll protein (PerCP)-Cy5.5-
conjugated CD34 antibody, phycoerythrin (PE)-conjugated
CD73 or CD105 antibodies, Allophycocyanin (APC)-conjugated
836 M. Maumus et al.CD13 or CD90 antibodies, APC-H7-conjugated CD45 antibody,
V450-conjugated CD11b or CD14 antibodies and V500-
conjugated HLA-DR antibody or the respective isotype controls
for 20 min at 4 °C in the dark. The labeled cells were then
analyzed by multiparameter flow cytometry using a FACSCanto
cytometer and the Diva software (BD-Bioscience).
Differentiation of ASCs
For adipogenesis, ASCs were seeded at the density of
10,000 cells/cm2 in proliferative medium for 5 days. The
medium was changed by DMEM-F12, PS, 16 μmol/L biotin,
18 μmol/L pantothenic acid, 100 μmol/L ascorbic acid, 5%
FCS, 1 μmol/L dexamethasone, 60 μmol/L indomethacin,
50 μmol/L IBMX and 10 μmol/L rosiglitazone, up to 21 days.
Adipogenesis was assessed by RT-qPCR and lipid droplets were
visualized bymicroscopy. Osteogenesis was induced by culture
at low density (3000 cells/cm2) in DMEM/PS/Glu/10% FCS,
10 mM β-glycerophosphate, 0.1 μmol/L dexamethasone and
50 μg/mL ascorbic acid for 21 days. Osteogenic differentiation
was assessed by RT-qPCR and extracellular matrix mineraliza-
tion detected by alizarin red S staining. Chondrogenic
differentiation was induced by culture of ASCs (2.5 × 105
cells) in micropellet as described (Bouffi et al., 2010b).
Chondrogenesis was assessed by RT-qPCR and immunohisto-
chemistry on paraffin sections of pellets using a 1/1000 dilution
of anti-aggrecan antibody (Chemicon, Millipore, Molsheim) and
the “Ultravision detection system anti-polyvalent HRP/DAB”
kit (Lab Vision, Francheville, France). Sections were
counterstained with Mayer's hematoxylin (Lab Vision) for
3 min and mounted with Eukitt (Sigma-Aldrich).
Co-culture assay
Chondrocytes (500,000 cells/well) were plated at high density
on the bottom of 6-well plates and cultured with ASCs or MSCs
(70,000 cells/insert) (ratio 7:1) in cell culture inserts (PET
membranes, 0.4 μm pore porosity, BD Biosciences). These
plating conditions correspond to confluent cultures in each
compartment. Cultures were maintained for 7 days in 3 mL of
minimal medium (DMEM supplemented with PS, proline
(0.35 mmol/L), ascorbic acid (0.17 mmol/L) and sodium
pyruvate (1 mmol/L)). Chondrocytes and ASCs were collected
for RT-qPCR analysis and supernatants were stored at −20 °C.
When indicated, isotypic control or anti-HGF antibody
(100 ng/mL; R&D Systems, Lille) was added during the
coculture.
Proliferation assay
Chondrocytes were plated at low density (40,000 cells/well)
in a 24well platewith or without ASCs (20,000 confluent cells/
insert) (ratio 2:1) or in proliferative medium. After 2 days,
chondrocyte number was evaluated using PrestoBlue™ assay
(Life-Technologies, Courtaboeuf, France).
Apoptosis evaluation
High density co-cultures (ratio 7:1) were initiated for 2 days
in the presence and in the absence of ASCs or 10% FCS. ASCswere then removed, media changed and 40 μM of
camptothecin was added on chondrocytes for 6 h (Bohm et
al., 2010). Chondrocytes were trypsinized and 1 × 105 cells
in suspension were labeled with PE-conjugated annexin V
antibodies (BD-Biosciences) in PBS containing 0.2% BSA for
20 min at 4 °C in the dark. Apoptotic chondrocytes were
quantified as the percentage of PE-annexin V positive cells
by flow cytometry analysis as described above. A second
assay for the detection of apoptotic cells relied on the use of
the Caspase-Glo® 3/7 Assay according to the manufacturer's
recommendations (Promega, Charbonnières, France). Re-
sults were expressed as the average Caspases 3/7 activities
detected in supernatants of lysed cells, either treated or not
with camptothecin, and normalized to the cell number as
measured using the CellTiter-Glo® Luminescent Cell Viabil-
ity Assay as recommended by the supplier (Promega).
RT-qPCR
Total RNA was extracted from cells using the RNeasy kit
(Qiagen, Courtaboeuf, France). RNA (0.5 μg) was reverse-
transcribed using the M-MLV enzyme (Fisher scientific,
Illkirch, France). Primers were designed using Primer3
software (see Table 1) and purchased by MWG (Eurofins-
genomics, Courtaboeuf, France). PCR reaction was carried out
on 25 ng of cDNA samples using 5 μmol/L of each primer and
5 μl 2× SybrGreen PCR Master Mix (Roche, Meylan, France).
The following conditionswere used: 95 °C for 5 min; 40 cycles
at 95 °C for 15 s; 64 °C for 10 s and 72 °C for 20 s in a
LightCycler 480 system (Roche diagnostics, Meylan, France)
and analyzed with the dedicated software. All values were
normalized to RPS9 housekeeping gene and expressed as
relative expression or fold change using the respective
formulae 2−ΔCT or 2−ΔΔCt.
Quantification of secreted factors
Supernatants from co-cultures were used to quantify IL-1
receptor antagonist (IL1-RA), IL-1β, TNF-α, MMP-1, MMP-9,
TIMP-1, TIMP-2, TSP-1, TGF-β1, and HGF by specific Enzyme-
linked immunosorbent assays (ELISA; R&D Systems). Inducible
NO synthase activity was quantified using colorimetric assays
as reported (Bouffi et al., 2010a).
Statistical analysis
Data were expressed as the mean ± SEM. Statistical analysis
was performed with GraphPad Prism software. The compar-
ison between the different groups was analyzed by repeated
one-way analysis of variance (ANOVA) followed by
Bonferroni post hoc test or with a Student's t test for two
groups.
Results
ASC phenotype and differentiation abilities
In concordance with our previous report, SC-ASCs expanded in
a medium containing fetal calf serum (FCS) exhibit a
fibroblastic morphology at passage 1 (Fig. 1A). They expressed
Table 1 Primer sequences.
Gene Sequence forward Sequence reverse
Aggregan TCGAGGACAGCGAGGCC TCGAGGGTGTAGCGTGTAGAGA
AP CCACGTCTTCACATTTGGTG GCAGTGAAGGGCTTCTTGTC
aP2 ATGGGATGGAAAATCAACCA GTGGAAGTGACGCCTTTCAT
Collagene I CCTGGATGCCATCAAAGTCT CGCCATACTCGAACTGGAAT
Collagen IIA ACGTGAAAGACTGCCTCAGC AGGAGGTCCTTTGGGTCCTA
Collagen IIB CAGACGCTGGTGCTGCT TCCTGGTTGCCGGACAT
Collagen III CGCCCTCCTAATGGTCAAGG AGGGCCTGAAGGACCAGCTT
Collagen VI AGCCGAAAACACCCTGCAAT CGTGAGGTCAGGCTTGGAAA
Collagen X TGCTGCCACAAATACCCTTT GTGGACCAGGAGTACCTTGC
HGF CCCCATCGCCATCCCCTATG ACATCTATTAGCACATTGGTCTGCAGT
Link TTCCACAAGCACAAACTTTACACAT GTGAAACTGAGTTTTGTATAACCTCTCAGT
LPL GTCCGTGGCTACCTGTCATT TGGATCGAGGCCAGTAATTC
MMP13 GACTTCCCAGGAATTGGTGA TACCCCAAATGCTCTTCAGG
RSP9 ATGAAGGACGGGATGTTCAC GATTACATCCTGGGCCTGAA
PPARγ CCAGAAAGCGATTCCTTCAC TGCAACCACTGGATCTGTTC
Osteocalcin GGCGCTACCTGTATCAATGG TCAGCCAACTCGTCACAGTC
RunX2 CGGAATGCCTCTGCTGTTAT TTCCCGAGGTCCATCTACTG
Sox9 AGGTGCTCAAAGGCTACGAC GTAATCCGGGTGGTCCTTCT
Vimentin AAGGCTACCGAGGCGATGAG AGCCCTTCGTGCCGTTTATC
837Adipose mesenchymal stem cells protect chondrocytes from degenerationthe classical MSC markers: CD13, CD73, CD90 and CD105 and
were negative for hematopoietic and endothelial markers:
HLA-DR, CD11b, CD14, CD31, CD34, CD45 and CD106 (Fig. 1A).
As expected, while the CD34 marker is detected on
tissue-resident MSCs (Lin et al., 2012; Maumus et al., 2011b),
its expression disappeared at the end of P1 after propagation
in culture. After induction of differentiation towards the three
specific lineages, ASCs gave rise to adipocytes, as shown by
the increased expression of peroxysome proliferator-
activated receptor (PPAR)-γ, lipoprotein lipase (LPL), fatty
acid binding protein (FABP)-4 and the presence of lipid
droplets in cultures, and compared to control ASCs cultured
in proliferative medium. ASCs differentiated into osteoblasts,
as shown by an increase in Runx2, alkaline phosphatase (AP),
osteocalcin (OC) expression and Alizarin Red S staining. They
also differentiated into chondrocytes, as indicated by an
enhanced expression of Sox9, aggrecan, collagen (col) type II
markers and anti-aggrecan immunostaining (Fig. 1B). Similar
results were obtained with the different sources of mesen-
chymal stem cells or expansion protocol (data not shown).Effect of ASC secretome on chondrocyte function
In order to evaluate the effect of ASCs on chondrocytes, a
co-culture assay was designed using the transwell system to
avoid cell–cell contact. We used chondrocytes and
sub-cutaneous (SC)-ASCs that were isolated and cultured in
proliferativemedium containing 10% FCSwhich corresponds to
routine laboratory culture conditions. Chondrocytes (lower
part) and ASCs (upper part) were plated in a minimal medium
to get rid of effects mediated by FCS. First, we investigated
the effect of ASCs on the proliferation of chondrocytes. We
therefore plated chondrocytes at low density allowing
proliferation of the cells. Chondrocytes, alone or in co-cultures with ASCs, did not proliferate in minimal medium,
while they proliferated in the presence of FCS (Fig. 2A).
Second, we analyzed the role of ASCs on confluent
chondrocytes induced to apoptosis using camptothecin and
high density conditions. In these conditions, the number of
annexin V+ chondrocytes was significantly decreased when
co-cultured with ASCs (Fig. 2B). Partial inhibition of apoptosis
was confirmed using a second assay where reduced levels of
apoptosis were observed both when chondrocytes were
cultured with ASCs or in the presence of FCS (Fig. 2C). Finally,
we evaluated the phenotype of chondrocytes in the co-culture
assay. In the presence of ASCs, chondrocytes maintained the
expression of aggrecan (Agg) and Sox9 while Col IIB expression
significantly decreased and Hyaluronan and Proteoglycan Link
Protein 1 (Link) expression was increased (Fig. 2D). However,
the expression of markers of hypertrophic chondrocytes:
metalloproteinase (MMP)-13, alkaline phosphatase (AP), and
Runx2 was significantly decreased and Col X tended to
diminish. Similarly, the expression of fibrotic markers:
collagens type I, III, VI and vimentin was all highly significantly
down-regulated in the presence of ASCs. Altogether, these
data demonstrate a potent role of SC-ASCs in the protection of
chondrocytes from apoptosis and loss of mature chondrocyte
phenotype to hypertrophic and fibrotic phenotypes which are
characteristics of OA.Effect of culture conditions and tissue origin of ASC
preparations on chondrocyte markers
Because clinical grade ASCs may be expanded using platelet-
enriched plasma (PLP) instead of FCS, we investigated
whether the culture conditions may influence the effect of
SC-ASCs on chondrocyte phenotype. We therefore compared
clinical grade SC-ASCs (Fig. 3A) and ASCs expanded with FCS
BAdipogenesis Osteogenesis Chondrogenesis
Pr
ol
ife
ra
tiv
e
m
ed
iu
m
D
iff
er
en
tia
tio
n
m
ed
iu
m
A CD34 CD106
CD90
HLA-DR
CD105
CD14 CD45
CD31
CD73CD13
CD11b
Co
un
ts
Co
un
ts
0
50
10
0
15
0
30
0
25
0
20
0
0
50
10
0
15
0
30
0
25
0
20
0
102 103 104 105 102 103 104 105 102 103 104 105 102 103 104 105
R
el
at
iv
e 
ex
pr
es
sio
n 
(2-
ΔC
T )
PPARγ FABP4 LPL
0.00
0.05
0.10
0.15
0.20
0.25 d0
d21
*
*
ND ND ND
Runx2 AP OC
0.0
0.1
0.2
0.3
**
Sox9 Agg
0.0
0.2
0.4
0.6
0.8
*
*
Col IIA
0
1×10-05
2×10-05
Figure 1 (A) Phenotype of human SC-ASCs: representative photomicrograph and histograms of flow-cytometry analysis of ASCs
stained with different antibodies. (B) Differentiation of SC-ASCs: adipogenesis is characterized by expression of peroxysome
proliferator-activated receptor (PPAR)-γ, FABP4 and lipoprotein lipase (LPL) and by the visualization of lipid droplets by phase
contrast microscopy in differentiation versus proliferative medium at day 21 (d21) versus d0. Osteogenesis is characterized by the
expression of Runx2, osteocalcin (OC), alkaline phosphatase (AP) and by Alizarin Red S positive staining in differentiation versus
proliferative medium. Chondrogenesis is characterized by the expression of Sox9, collagen IIA (col IIA) and aggrecan (Agg) and by
anti-aggrecan positive staining on pellet sections (lower panel) versus undifferentiated control section (upper panel). Results are
expressed as relative expression (2−ΔCT) and represented as mean ± sem for 3 independent biological replicates. ND: not detected;
*p b 0.05, **p b 0.01.
838 M. Maumus et al.using routine laboratory conditions (Fig. 2C). Both cell
samples were equally efficient to reduce the expression of
a set of hypertrophic and fibrotic markers on chondrocytes(data not shown for the other markers). Moreover, clinical
grade SC-ASCs were able to maintain the expression of Col
IIB in chondrocytes although mRNA levels of Sox9 were
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Figure 2 (A) The effect of ASCs on chondrocyte proliferation was evaluated after 2 days of co-culture in minimal medium using a
PrestoBlue assay. Results are expressed as the percentage of control (chondrocytes alone) and represented as mean ± sem (n = 9
biological replicates). (B) Percentage of annexin V+ apoptotic chondrocytes as evaluated by flow-cytometry analysis of
camptothecin-treated chondrocytes after 2 days of co-culture in minimal medium (mean ± sem, n = 9 biological replicates).
(C) Evaluation of apoptosis in camptothecin-treated chondrocytes after 2 days of co-culture in minimal medium, with or without ASCs
or 10% FCS, and determined by caspase 3/7 activities normalized to the number of cells (mean ± sem, n = 4 biological replicates).
(D) Expression of chondrocytic (aggregan (Agg), collagen IIB (Col IIB), Link and Sox9), hypertrophic (MMP13, alkaline phosphatase
(AP), Runx2 and collagen X (Col X)) and fibroblastic (Col I, III, VI and vimentin (Vim)) markers in chondrocytes co-cultured with ASCs
from subcutaneous abdominal fat (SC-ASCs). Results are expressed as fold change of gene expression compared to chondrocytes alone
(mean ± sem (n = 10 biological replicates)). *p ≤ 0.05, **p b 0.01, ***p b 0.001.
839Adipose mesenchymal stem cells protect chondrocytes from degenerationdecreased (Fig. 3A). We also evaluated ASCs isolated from
diverse locations. Clinical grade expanded Hoffa- and
Hip-ASCs were able to reduce the expression level of at
least two tested markers. Hoffa-ASCs did not reduce the
expression of fibrotic markers (Fig. 3B), while Hip-ASCs
significantly decreased expression of Agg, Col IIB and Sox 9
(Fig. 3C). Finally, we evaluated bone marrow-derived MSCs
and obtained similar effects as SC-ASC on the expression of
fibrotic and mature chondrocyte markers, except for Sox9
and AP whose expression was not down-regulated with
BM-MSCs (Fig. 3D). Although direct comparison between
ASCs from diverse locations and MSCs was prevented by the
difficulty to get cells from the same subjects, our data
suggest that SC-ASCs, when expanded under good laboratory
practice conditions in the presence of PLP, appeared to bean interesting source of stem cells for a protective effect on
OA chondrocytes.Secretory profile of chondrocyte and ASC co-cultures
We then quantified the secretion of several factors known to
bemodulated during the course of OA. Passage 1 chondrocytes
and ASCs, alone or in co-culture, did not secrete mediators
involved in inflammation such as interleukin (IL)-1β, Tumor
Necrosis Factor (TNF)-α, Matrix Metalloproteinase (MMP)-9 or
nitric oxide (NO). IL-1Receptor Antagonist (IL1-RA) was highly
produced by chondrocytes and poorly by ASCs while its
secretion was not modulated in co-cultures (Fig. 4). Same
results were obtained for factors involved in matrix
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phosphatase (AP)) and fibroblastic (Col I and III) markers on
chondrocytes co-cultured with ASCs from subcutaneous abdomi-
nal fat (SC-ASCs) (A), infrapatellar fat (Hoffa-ASCs) (B), subcuta-
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chondrocytes alone (mean ± sem (n = 7–18 biological repli-
cates)). *p b 0.05, **p b 0.01, ***p b 0.001.
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840 M. Maumus et al.remodeling namely, thrombospondin (TSP)-1, Tissue Inhibitor
of Metalloproteinase (TIMP)-1, TIMP-2 and MMP-1. On the
contrary, Transforming Growth Factor (TGF)-β1 which is aknown pro-fibrotic factor was secreted only by chondrocytes
and not ASCs. Interestingly, in the co-cultures, the secretion
of TGF-β1 was significantly reduced by 40% further suggesting
an anti-fibrotic effect of ASCs on OA chondrocytes.
The anti-fibrotic effect of ASCs is mediated by HGF
In the search for an anti-fibrotic factor secreted by ASCs, we
focused on Hepatocyte Growth Factor (HGF). Indeed, high
levels of HGF were detected in the supernatants of ASCs
or co-cultures but not in chondrocyte supernatants (Fig. 5A).
We then quantified the level of mRNA in chondrocytes and
ASCs, when cultured alone or together, to identify the
HGF-producing cells. Although low level of HGF mRNA was
expressed in chondrocytes, high expression was detected in
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Figure 5 (A) HGF protein was quantified in the supernatants of
chondrocytes alone (white bar), ASCs alone (black bar) or the
co-culture (gray bar) by ELISA. Results are expressed as the
concentration of cytokine (mean ± sem, n = 15 biological repli-
cates). (B) HGFmRNA level wasmeasured by RT-qPCR in cells alone
(Chondro or ASC) or co-cultured. Results are expressed as
fold change of gene expression compared to chondrocytes alone
(2−ΔΔCT) and represented as mean ± sem (n = 15 biological
replicates). (C–F) Expression of markers on chondrocytes co-
cultured with SC-ASCs in the presence or absence of a neutralizing
anti-HGF antibody or its isotype control (100 ng/mL) for 7 days.
Results are expressed as fold change of gene expression compared
to chondrocytes alone (mean ± sem (n = 13 replicates)).
*p b 0.05, **p b 0.01, ***p b 0.001, ND = not detected.
841Adipose mesenchymal stem cells protect chondrocytes from degenerationASCs and it was significantly increased in the co-cultures
(Fig. 5B). To confirm the role of HGF, we used a neutralizing
antibody directed against HGF in the cocultures. Addition of
the neutralizing antibody reversed the effect of ASCs on
expression levels of the fibrotic markers Col I and Col III while
the isotypic control did not (Figs. 5C-D). Importantly, the
anti-HGF or isotypic antibodies did not modify the expression
of MMP13 while the reversion of AP expression was observed
both with the anti-HGF and isotypic control antibodies
(Figs. 5E-F). These results suggest that HGF secretion is not
responsible for the anti-hypertrophic effect observed withASCs and demonstrate that chondrocytes activate ASCs to
display an anti-fibrotic effect that is mediated to a large
extend by HGF.Discussion
The present study demonstrates for the first time that ASCs
secrete molecules that exert a chondroprotective effect
through the reduction of hypertrophic and fibrotic pheno-
types, which characterize OA chondrocytes, as well as a
protective role from apoptosis. We further establish that HGF
is at least partly responsible for the anti-fibrotic effect
mediated by ASCs.
While ASCs are considered amore accessible source of cells
than MSCs, both cells exhibit similar properties and are
considered as promising tools for tissue engineering and cell
therapy applications (Maumus et al., 2011a). Previously, a
number of studies investigated the cross-talk between MSCs
and chondrocytes and most of the studies reported the role of
chondrocytes on the differentiation of MSCs. Differentiation of
MSCs, showed by up-regulation of Col II and aggregan
expression as well as GAG production, occurred via the
secretion of factors such as Parathyroid Hormone related
Peptide (PTHrP), TGFβ, Insulin Growth Factor (IGF)-1 or Bone
morphogenetic protein (BMP)-2 by chondrocytes (Acharya
et al., 2012; Aung et al., 2011; Fischer et al., 2010; Liu et al.,
2010). Conversely, other studies reported that the addition of
MSCs increased cartilagematrix production by chondrocytes in
co-culture (Giovannini et al., 2010; Mo et al., 2009; Wu et al.,
2011, 2012). However, all these reports used MSCs in direct
contact with chondrocytes cultured in pellet and under
chondroinductive conditions. In these studies, the addition
of fat- or BM-derived MSCs resulted in the absence or slight
increase of cartilage matrix production by chondrocytes or
enhanced proliferation. We therefore investigated the role of
ASCs on chondrocytes using a co-culture assay in which OA
chondrocytes are cultured in monolayer which is a condition
close to the altered phenotype occurring during OA and in a
minimal medium to see a direct effect of ASCs, independently
of FCS or growth factors contained in chondroinductive
medium. We also cultured chondrocytes in a transwell culture
system to avoid direct contact with ASCs and evaluated the
effect of diffusible molecules. Contrary to previous reports, in
our conditions, we did not observe an increased proliferation
rate or enhanced production of cartilaginous matrix by
chondrocytes, likely due to the absence of chondro-inductive
components. However, we were able to rather demonstrate a
dual protective role of ASCs on chondrocytes, which was not
described previously. ASCs decrease the expression of fibrotic
markers, indicative of dedifferentiation towards fibroblast-
like cells, and of hypertrophic markers, both hallmarks of OA
chondrocytes. These properties were broadly shared by
mesenchymal stem cells isolated from bone marrow or fat
from different locations. ASCs from diverse fat tissue locations
were tested because they display distinct secretomes andmay
differ in terms of functional properties (Jurgens et al., 2008,
2009; Schipper et al., 2008). Our findings therefore validate
the interest of using mesenchymal stem cells, in particular
from adipose tissue, not only for chondroinductive effect as
shown by some other studies but also for a chondroprotective
role decreasing the propensity of OA chondrocytes to become
842 M. Maumus et al.fibrotic or hypertrophic. Moreover, the present study provides
mechanistic insight with which MSCs or ASCs may exert their
therapeutic effect in vivo when implanted in the joints of
animals with osteoarthritis (Diekman et al., in press; Murphy
et al., 2003; Ter Huurne et al., 2012).
We showed that the mechanism of chondroprotection
is associated with the down-regulation of TGF-β1 in
chondrocytes. Although not investigated and not demonstrat-
ed here, the reduced TGF-β1 secretion by chondrocytes when
co-cultured with ASCs might down-regulate ALK1-Smad1/5/8
signaling that has been described to induce Runx2 activation
and MMP13 secretion in OA chondrocytes and therefore
explain the lower expression of hypertrophic markers (van
der Kraan et al., 2012). Since TGF-β1 is also known to be
pro-fibrotic, its down-regulation might also explain the
anti-fibrotic effect of ASCs (Biernacka et al., 2011). Together
with the decrease of TGF-β1 in chondrocytes, we observed the
increase of HGF secretion by ASCs. HGF, which is mainly
secreted by stromal cells, is known to participate in tissue
protection and regeneration, promoting cell survival, prolif-
eration and stimulating extracellular matrix degradation
(Nakamura et al., 2011). The anti-fibrotic effect of MSCs
through HGF secretion is documented in several diseases such
as heart failure, bladder or kidney fibrosis but was never
reported in OA (Liu et al., 2011; Shabbir et al., 2009; Song et
al., 2012). Although it was reported that chondrocytes do not
produce functional HGF (Bau et al., 2004; Guevremont et al.,
2003; Pfander et al., 1999), the protein is detected in synovial
fluid and its concentration is positively correlated with the
severity of OA (Dankbar et al., 2007) while HGF increases
proteoglycan synthesis in rabbit chondrocytes (Bau et al.,
2004; Takebayashi et al., 1995). In our settings, we showed
that HGFmediates the decrease of Col type I and III expression
by OA chondrocytes. Moreover, up-regulation of HGF secretion
by ASCs co-cultured with chondrocytes argues for a cross-talk
between the two cell types. Even though the cross-talk clearly
influences the range of HGF secretion, it is likely not required
for a measurable effect on chondrocytes, as suggested
by another study in a model of heart failure where the
intramuscular injection of MSC conditioned medium allowed a
regenerative process on the infarcted myocardium (Shabbir
et al., 2009). The mechanism by which HGF mediates an
anti-fibrotic role in chondrocytes has still to be investigated.
However, possible explanation may be through the induction
of connective tissue growth factor (CTGF), which suppresses
collagen I synthesis (Inoue et al., 2003). It may also be
explained by the induction of various matrix metallo-
proteinases, in particular MMP-1, -2, -9 which are crucial in
matrix remodeling by denaturing collagens type I, III or IV (Lee
et al., 2011; Sherriff-Tadano et al., 2006). While we identified
HGF as a secreted factor playing a key role in the anti-fibrotic
effect of ASCs on OA chondrocytes, we cannot however
exclude that other released factors may contribute to this
effect. Proteomic analysis of supernatants from co-culture
and that of cells cultured alone might help identifying other
molecules potentially involved in the chondroprotective role
of ASCs on chondrocytes (Skalnikova et al., 2011).
Besides their direct effect on cartilage, ASCs might act on
the other joint tissues as synovial membrane, ligaments,
meniscus and subchondral bone that are also altered in OA.
Although OA is not considered an inflammatory disease,
pro-inflammatory cytokines, namely IL-1β and TNF-α, aresecreted by OA chondrocytes and synoviocytes and, partic-
ipate to joint tissue alterations. Results from a collaborative
work report that several pro-inflammatory cytokines are
significantly down-regulated in chondrocytes when cultured
with ASCs suggesting that ASCs may also be protective through
the down-regulation of inflammatory mediators (Manferdini
et al., 2013). Moreover, using the pre-clinical murinemodel of
collagenase-induced OA, we recently described that a single
ASC injection in the knee joint of mice inhibited synovial
activation and formation of chondrophyte/osteophyte in joint
ligaments as well as cartilage destruction, probably by
suppressing synovial macrophages (Ter Huurne et al., 2012).
All these data argue in favor of a trophic action of ASCs for
protecting endogenous cartilage from degradation. Here, we
demonstrated a pleiotropic action of ASCs on fibrosis,
hypertrophy and apoptosis and, proposed HGF as one soluble
mediator that participates to this overall effect. These results
are promising preclinical data which confirm the interest of
using ASCs in cell-based therapies for osteo-articular diseases
by mediating chondroprotection in the joints of patients.
Ongoing clinical trials should help addressing the efficacy of
ASCs in the treatment of OA.
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